Upgrade to SI Premium - Free Trial

Guggenheim Reiterates Buy Rating on Abbvie (ABBV)

March 12, 2026 6:55 AM
Guggenheim analyst Vamil Divan reiterated a Buy rating and $242.00 price target on Abbvie (NYSE: ABBV).The analyst commented: "UCB (UCB.BR) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments